TASL and renal cell carcinoma: The analysis revealed that in BLCA, KIRC, RCC, and SKCM, the immunotherapy response rates were higher in the high TASL expression group (Fig. 4A), and the TASL expression levels were higher or marginally higher in immunotherapy responders (R) than in non-responders (NR) (KIRC (aPD1), P = 0.014; RCC-GSE67501, P = 0.246; SKCM-GSE100797, P = 0.036; SKCM-GSE91061-prog, P = 0.058; Fig. 4B).